Literature DB >> 32169970

Secukinumab efficacy in patients with PsA is not dependent on patients' body mass index.

Ilenia Pantano1, Daniela Iacono1, Ennio Giulio Favalli2, Giuseppe Scalise1, Luisa Costa3, Francesco Caso3, Giuliana Guggino4, Raffaele Scarpa3, Francesco Ciccia5.   

Abstract

Entities:  

Keywords:  DMARDs (biologic); psoriatic arthritis; treatment

Mesh：

Substances：

Year:  2020        PMID： 32169970     DOI： 10.1136/annrheumdis-2020-217251

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  11 in total

1.  A Machine Learning Approach to Predict Remission in Patients With Psoriatic Arthritis on Treatment With Secukinumab.

Authors:  Vincenzo Venerito; Giuseppe Lopalco; Anna Abbruzzese; Sergio Colella; Maria Morrone; Sabina Tangaro; Florenzo Iannone
Journal:  Front Immunol       Date:  2022-06-27       Impact factor: 8.786

2.  Severe Disease in Patients With Recent-Onset Psoriatic Arthritis. Prediction Model Based on Machine Learning.

Authors:  Rubén Queiro; Daniel Seoane-Mato; Ana Laiz; Eva Galindez Agirregoikoa; Carlos Montilla; Hye Sang Park; Jose A Pinto Tasende; Juan José Bethencourt Baute; Beatriz Joven Ibáñez; Elide Toniolo; Julio Ramírez; Cristina Pruenza García-Hinojosa
Journal:  Front Med (Lausanne)       Date:  2022-04-28

Review 3.  Psoriatic Arthritis and Metabolic Syndrome: Is There a Role for Disease Modifying Anti-Rheumatic Drugs?

Authors:  Fabiola Atzeni; Elisabetta Gerratana; Ignazio Francesco Masala; Sara Bongiovanni; Piercarlo Sarzi-Puttini; Javier Rodríguez-Carrio
Journal:  Front Med (Lausanne)       Date:  2021-08-30

Review 4.  Psoriatic arthritis and the association with cardiometabolic disease: a narrative review.

Authors:  Paras Karmacharya; Alexis Ogdie; Lihi Eder
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-03-02       Impact factor: 5.346

Review 5.  Adipokines, Cardiovascular Risk, and Therapeutic Management in Obesity and Psoriatic Arthritis.

Authors:  Sabrina Porta; Matilde Otero-Losada; Rodolfo A Kölliker Frers; Vanesa Cosentino; Eduardo Kerzberg; Francisco Capani
Journal:  Front Immunol       Date:  2021-02-10       Impact factor: 7.561

6.  Association of Gender, Diagnosis, and Obesity With Retention Rate of Secukinumab in Spondyloarthropathies: Results Form a Multicenter Real-World Study.

Authors:  Alicia García-Dorta; Paola León-Suarez; Sonia Peña; Marta Hernández-Díaz; Carlos Rodríguez-Lozano; Enrique González-Dávila; María Vanesa Hernández-Hernández; Federico Díaz-González
Journal:  Front Med (Lausanne)       Date:  2022-01-13

Review 7.  Metabolic Syndrome and Its Components in Psoriatic Arthritis.

Authors:  Roaa Aljohani
Journal:  Open Access Rheumatol       Date:  2022-02-17

Review 8.  Psoriatic Arthritis: The Influence of Co-morbidities on Drug Choice.

Authors:  Sneha Patel; Anand Kumthekar
Journal:  Rheumatol Ther       Date:  2021-11-19

9.  Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies.

Authors:  Christopher T Ritchlin; Philip J Mease; Wolf-Henning Boehncke; John Tesser; Elena Schiopu; Soumya D Chakravarty; Alexa P Kollmeier; Xie L Xu; May Shawi; Yusang Jiang; Shihong Sheng; Yanli Wang; Stephen Xu; Joseph F Merola; Iain B McInnes; Atul Deodhar
Journal:  RMD Open       Date:  2022-03

Review 10.  Choosing the Appropriate Target for the Treatment of Psoriatic Arthritis: TNFα, IL-17, IL-23 or JAK Inhibitors?

Authors:  Chrysoula G Gialouri; Gerasimos Evangelatos; George E Fragoulis
Journal:  Mediterr J Rheumatol       Date:  2022-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.